Advertisements

Covonia Cold & Flu

Quick links to important sections

Covonia Cold & Flu

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Covonia Cold & Flu

Quick Facts Description
Active ingredients Paracetamol, Phenylephrine HCl, Guaifenesin, Cetylpyridinium Chloride
Form Oral Solution (Liquid)
Pharmacological class Multi-component: Analgesic, Decongestant, Expectorant, Antiseptic
Common purpose Comprehensive symptomatic relief for cold and flu
Origin Synthetic

What Kind of Medicine is Covonia Cold & Flu?

Covonia Cold & Flu is classified as a multi-component medicinal product, meaning it is formulated to address several symptoms of a cold or flu simultaneously using four different active substances. It encompasses several actions: it acts as an analgesic/antipyretic, a decongestant, an expectorant, and a local antiseptic. For instance, the combination of a decongestant and a pain reliever is used for providing short-term relief from common cold symptoms. This specific formulation is distinguished by its four-way action, targeting both systemic symptoms like fever and localized symptoms like a congested nose and productive cough.


What Active Ingredients and Form Does It Contain?

This medicine is a liquid formulation known as an Oral Solution, designed for the oral route of administration. Its four key active ingredients [INN] are Paracetamol (for pain and fever), Phenylephrine hydrochloride (a nasal decongestant), Guaifenesin (an expectorant), and Cetylpyridinium chloride (a throat antiseptic). The inclusion of Guaifenesin, in particular, is intended to help thin and loosen mucus in the chest, a mechanism relied upon for relief from a productive cough. The liquid form, prepared using an aqueous/hydroalcoholic base, is often preferred by patients as it is easy to swallow and may provide a soothing sensation upon contact with a sore throat.


What is the General Purpose of This Combination?

The general purpose of this combination medicine is to provide comprehensive, multi-symptom relief to maximize patient comfort throughout the duration of a cold or flu. By merging four distinct therapeutic actions, the product is engineered to effectively manage a range of discomforting issues simultaneously, including systemic problems like fever and localized issues like nasal congestion and chest congestion. This integrated approach helps to reduce overall malaise and supports easier breathing, providing a more holistic symptomatic response than a targeted, single-ingredient medicine.

Advertisements

What side effects are possible with Covonia Cold & Flu?

Possible Side Effects and Safety Information

The officially documented safety profile for this multi-component medicine is structured around adverse reactions classified by frequency and the physiological systems affected. These classifications are consistent with government regulatory standards.


Adverse Reaction Classifications

Side effects are grouped by incidence, as reported in regulatory documents:

  • Rare (ge 1/10,000 to <1/1,000): Effects such as tachycardia (increased heart rate), hypertension (high blood pressure), and liver function test abnormalities have been associated with components of the formulation.
  • Very Rare (le 1/10,000): Includes serious adverse reactions such as certain blood dyscrasias (e.g., agranulocytosis) and severe cutaneous adverse reactions (SCARs).
  • Not Known: Reactions such as anaphylactic shock and urinary retention where frequency cannot be estimated from available data are documented.

Adverse reactions are also classified by System-Organ-Class (SOC), including effects on the Blood and Lymphatic System, Cardiac and Vascular Systems, Nervous System, and Hepatobiliary Disorders.


Safety Constraints and Special Considerations

The regulatory label outlines specific constraints on use. The product is formally contraindicated in patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of cessation. Use is restricted if the patient is taking other products containing Paracetamol or Phenylephrine.

Population-specific safety cautions are documented for individuals with pre-existing conditions. The medicine is contraindicated in patients with severe coronary heart disease or uncontrolled hypertension. Caution is advised for those with severe renal or hepatic impairment, diabetes, or an enlarged prostate gland.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help


Required Emergency Actions

The official regulatory statement is that immediate medical advice must be sought for any suspected overdose, even if no initial symptoms are present. Patients must be referred to hospital urgently for immediate medical attention. This mandatory action is required due to the risk of delayed, serious liver damage associated with the paracetamol component, which can progress without early warning signs.


Documented Clinical Manifestations

Initial overdose presentations commonly include non-specific symptoms such as pallor, nausea, vomiting, anorexia, and abdominal pain. Due to the phenylephrine component, a significant hypertensive response and associated reflex bradycardia may also manifest acutely. More severe outcomes, including signs of liver damage, abnormalities of glucose metabolism, metabolic acidosis, and acute renal failure may become apparent 12 to 48 hours post-ingestion.


Severe Outcomes and Antidotal Treatment

In severe poisoning, hepatic failure can progress to life-threatening complications, including encephalopathy, cerebral oedema, coma, and death. The specific antidote for paracetamol toxicity, N-acetylcysteine, is documented for use, with its maximal protective effect noted within eight hours of ingestion. Supportive measures described include administering activated charcoal if ingestion was within one hour and treating the hypertensive response with an alpha-antagonist. The risk of liver damage is noted to be greater in patients with glutathione depletion states or regular excessive ethanol consumption.

Advertisements

Therapeutic Uses of Covonia Cold & Flu

What Covonia Cold & Flu Treats: Main Uses and Benefits

Covonia Cold & Flu is generally used for the short-term symptomatic relief of common, acute manifestations associated with colds and influenza (the flu). It addresses symptom clusters that may create noticeable physiological strain, applied across domains where short-term symptomatic support is needed. Its use is intended for managing these conditions through the relief of associated symptoms.


Support for Systemic and Respiratory Symptoms

This medication is applicable within therapeutic areas involving symptoms related to systemic imbalance and respiratory irritation. It is used for managing certain distressing symptoms, including aches, pains, headache, fever, blocked nose, chesty cough, and sore throat. Providing this support may help ease the overall symptom burden, and it is commonly applied during phases when symptoms become more noticeable and short-term assistance is sought.

Quick Fact: Addressing Multiple Symptom Axes

This supportive treatment is commonly used when symptoms related to physical discomfort and respiratory irritation occur together, assisting with maintaining functional stability during symptomatic episodes.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Covonia Cold & Flu?

This section outlines the officially documented population eligibility rules for Covonia Cold & Flu Oral Solution, based strictly on government-approved regulatory labeling.


Approved and Restricted Age Groups

Age Group Eligibility Status
Children under 12 years Contraindicated (Must not be used)
Adolescents (12–16 years) Approved for use, subject to specific dosage restrictions.
Adults and The Elderly Approved for standard use.

Absolute Contraindications (Do Not Use)

The medicine is contraindicated and must not be used by certain populations due to risk, as defined by regulatory documents:

  • Individuals with a known hypersensitivity to Paracetamol, Phenylephrine, Guaifenesin, or any other ingredient.
  • Individuals who are pregnant or currently taking Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping MAOIs.
  • Patients with severe coronary artery disease, severe hypertension, or phaeochromocytoma.
  • Individuals currently taking other medicines containing paracetamol or other cold/flu decongestants.

Conditions Requiring Caution

Use of this medicine requires specific caution in patients with conditions such as liver disease, kidney problems, diabetes, glaucoma, high blood pressure, or an overactive thyroid gland. It is generally not recommended for women who are breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Covonia Cold & Flu, which contains Paracetamol, Phenylephrine HCl, and Guaifenesin, is defined by several regulatory restrictions and warnings regarding co-administration with other substances.

Formal Combination Restrictions

Co-administration with Non-selective Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the risk of severe pressor effects and hyperthermia from Phenylephrine; this restriction applies for up to 15 days after the MAOI is discontinued. The product must also not be taken with other Paracetamol-containing products to avoid exceeding the maximum daily dose and risking severe hepatic injury.

Pharmacodynamic and Metabolic Interactions

Interactions involving Phenylephrine can lead to potentiation of pressor effects when combined with medicines such as Tricyclic Antidepressants (TCAs), risking paroxysmal hypertension. The Paracetamol component interacts with anticoagulants like Warfarin, where chronic daily use may cause a clinically significant increase in the International Normalized Ratio (INR) and an elevated bleeding risk. Furthermore, substances classified as Hepatic Enzyme Inducers may increase Paracetamol's hepatotoxic potential.

Other Documented Constraints

Probenecid is documented to increase Paracetamol plasma exposure by reducing its clearance. The active ingredient Guaifenesin may interfere with certain colorimetric laboratory tests for substances like 5-HIAA and VMA. Finally, consumption of Alcohol poses an increased risk of severe hepatotoxicity when combined with Paracetamol.

Advertisements

Mechanism of Action

Central Modulation of Temperature and Pain Signaling

The action begins with Paracetamol's selective inhibition of COX-2 primarily within the central nervous system (CNS). This mechanism reduces the synthesis of PGE2 in the hypothalamus, modulating the body's thermal set point. This central modulation directly initiates peripheral vasodilation and heat dissipation, leading to a reduction of an elevated core body temperature and attenuated central nociceptive signaling.


Autonomic Vasoconstriction in Nasal Mucosa

Phenylephrine acts as a direct agonist on alpha1-ARs found on the vascular smooth muscle cells of mucosal arterioles. This targeted receptor activation triggers vasoconstriction, which physically decreases the local blood flow to the nasal and sinus lining. The resulting reduction in fluid leakage and interstitial volume is the mechanism that reduces tissue fluid accumulation (edema).


Reflex Enhancement of Airway Secretion

The expectorant component, Guaifenesin, operates via an irritant/stimulatory mechanism, engaging the gastro-pulmonary vagal reflex arc and directly increasing the secretory activity of bronchial glands. This action modifies the rheology of the secretions by adding a greater volume of watery fluid, making the dense, sticky mucus more fluid and supporting mucociliary clearance from the lower airways.


Local Microbial Surface Disruption

The local antiseptic component, Cetylpyridinium Chloride, provides a surface-level mechanism by acting as a cationic surfactant. This activity leads to the physical disruption of microbial cell membranes in the oropharynx. This mechanism is confined to the surface of the throat, resulting in disrupted microbial integrity on the mucosal surface.

Advertisements

Dosage and Administration Information

The medicine is a liquid solution strictly intended for the oral route of administration. Its use involves standardized preparation steps and fixed dosing schedules for short-term symptomatic support.


Administration Protocol and Dosing Limits

The administration process requires specific procedural steps before consumption. The bottle must be shaken for at least ten seconds to ensure proper content mixture. Dosing must always be measured using the supplied measuring cup to ensure the correct volume is delivered.

Age Group Single Dose Volume Maximum Doses in 24 Hours
Adults, Elderly, & Children 16 years and over 20 ml 4
Children 12–16 years 15 ml 4

Frequency and Special Conditions

The dosing frequency is fixed, requiring a minimum interval of at least four hours between administrations to prevent exceeding the maximum intake limit, which is four doses per 24 hours. The use of this product is designated as short-term only. It is not recommended for children under 12 years unless a physician directs otherwise. If a dose is missed, it should be taken as soon as the lapse is remembered; however, instructions strictly prohibit taking a double dose to compensate for the omission.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Covonia Cold & Flu

Evidence for Relief of Pain and Fever (Analgesic Component)

Research has widely examined the analgesic ingredient (Paracetamol) of this medicine. This component was studied to evaluate its influence on outcomes related to systemic or functional imbalance, such as body temperature, and outcomes related to physical discomfort, specifically headache, sore throat, and body aches. The research base includes extensive systematic reviews and controlled trials that monitor these physiological and patient-reported outcomes over short time intervals. Findings describe patterns observed in the studies where this ingredient has been consistently monitored for changes in temperature and pain intensity in adults and children presenting with acute symptoms. This evidence contributes to the broader evidence landscape often referenced by regulators for short-term symptomatic use.

The specialized studies monitoring the fever and pain component draw predominantly from data on monotherapy (the single ingredient alone). This means that the role of the analgesic is widely referenced in the literature, but the specific research examining its contribution within this particular four-ingredient cold and flu formula is limited.


Evidence for Multi-Symptom Management (Combination Approach)

The multi-symptom approach was evaluated in various short-term, randomized controlled trials (RCTs) and systematic reviews that focus on similar combination cold and flu products. These studies research examined a broad range of outcomes reflecting daily functioning or activity level and outcomes describing episodic or acute changes in a patient’s overall condition. Researchers used measures like the Total Symptom Score (TSS) to monitor patient-reported experiences across multiple symptoms—such as congestion, pain, and fever—simultaneously.

Studies help show what has been observed so far, and some trials report patterns suggesting that combination products may be associated with differences in overall symptom scores compared to a neutral placebo. However, the evidence is often derived from settings with varying symptom burdens and different active ingredient ratios. Follow-up durations were limited, typically lasting only the acute phase of the illness (around 3 to 10 days).


Evidence for Congestion and Cough Components

This section outlines the research focused on the two components intended to address respiratory and chest symptoms: the oral decongestant and the expectorant.

Research Focus on Nasal Congestion Relief (Phenylephrine)

Findings were mixed across various controlled trials when comparing the oral ingredient to a placebo for decongestion. Data show patterns related to absorption of the oral ingredient into the bloodstream, and regulatory bodies have noted that the evidence appears to not consistently support its effectiveness as a nasal decongestant at the doses found in non-prescription products. Therefore, scientific certainty remains low in this area.

Research Focus on Productive Cough (Guaifenesin)

Findings describe patterns observed in the studies that may suggest patterns related to changes in mucus characteristics and the frequency of productive cough. However, establishing a consistent, reliable clinical measure for expectorant activity in the context of an acute cold was associated with difficulty, and results were observed in some studies to be inconsistent.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Covonia Cold & Flu (FAQ)

Q: What happens if I miss a scheduled dose?

Official product information states that if a dose is forgotten, it should be taken as soon as the lapse is remembered. It is very important that a double dose is not taken to compensate for the one that was missed, as this could risk exceeding the maximum daily intake. The subsequent dose is typically continued at the regular minimum interval.


Q: How long should I keep taking the medicine if my symptoms persist?

This product is only intended for short-term use. If cold or flu symptoms do not improve or worsen, regulatory documents indicate that a doctor or healthcare professional should be consulted. The product information recommends against indefinite use.


Q: What is the minimum age a child can be to take this?

Official eligibility rules state that the medicine is not recommended for children under 12 years of age. The product is generally not recommended for this age group unless a doctor specifically advises its use.


Q: Is it safe to drive after taking this medicine?

Regulatory information indicates the medicine contains a percentage of alcohol (ethanol). While the amount is unlikely to affect most adults and adolescents, it may cause effects such as feeling drowsy or sleepy in younger children. The official product information does not include an explicit warning or recommendation regarding driving or operating machinery.


Q: What should I do if I accidentally take too much?

If more than the recommended amount is accidentally taken, immediate medical advice should be sought. This is crucial even if the person feels well. Having the medicine pack available can assist healthcare providers, as an overdose carries a risk of serious, delayed liver damage.


Q: Does this product contain any sugar or alcohol?

According to the official product information, this medicine is sugar-free but contains liquid maltitol and sorbitol, which are sources of fructose. It also contains alcohol (ethanol), with a 20 ml dose containing 2880 mg of alcohol.

Advertisements

How should Covonia Cold & Flu be stored and disposed of?

How to Store and Dispose of Covonia Cold & Flu Formula

The storage and disposal of Covonia Cold & Flu Formula Oral Solution are strictly governed by official regulatory requirements to maintain product quality and protect the environment.


Storage Requirements

The medicine must not be stored above 25 C. The container must be kept tightly closed and stored in the original outer carton to protect the liquid from light and other factors. A mandatory child-safety measure requires the product to be kept out of the sight and reach of children at all times. The product must not be used after the expiry date printed on the carton.


Disposal Instructions

Official instructions strictly prohibit disposing of the medicine via wastewater or regular household waste. Patients are required to ask a pharmacist for the correct procedure on how to dispose of any unused or expired product. These steps ensure environmentally protective handling of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Covonia Cold & Flu found in:

A-Z Index: